# Barbara Dalton

> Barbara Dalton is a Series A investor at Pfizer (New York) backing Biotechnology and Health Care. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Pfizer](https://shizune.co/investors/profile/pfizer)
- Location: New York, United States
- Total investments: 9
- Last investment: Nov 2025
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/barbara-dalton-4125a97

Barbara Dalton is a Series A investor at Pfizer in New York focused on Biotechnology and Health Care. Barbara Dalton - Senior Managing Partner, Pfizer Ventures; VP, Worldwide Business Development @ Pfizer

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 78% |
| Health Care | 4 | 44% |
| Therapeutics | 3 | 33% |
| Medical Device | 2 | 22% |
| Medical | 1 | 11% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 22% |
| Series B | 2 | 22% |
| Series C | 2 | 22% |
| Funding Round | 2 | 22% |
| Series D | 1 | 11% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 5 | 56% |
| United Kingdom | 2 | 22% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Artios Pharma | Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a uniquepartnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK. | $115M | Series D | Nov 17, 2025 |  |
| Artios Pharma | Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a uniquepartnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK. | $152.7M | Series C | Jul 27, 2021 |  |
| Artios Pharma | Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a uniquepartnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK. | $85.1M | Series B | Aug 10, 2018 |  |
| Complexa | Complexa is a clinical-stage platform biopharmaceutical company researching and developing endogenous human cell signaling technologies targeting an array of prevalent inflammatory, fibrotic, and CNS diseases. The company's proprietary technology involves the synthesis and therapeutic applications of endogenous nitro-fatty acids (NFAs) andadditional structure/function-related mediators that are designed to treat various diseases. NFAs are cell-signaling agents that regulate major inflammatory signaling pathways (e.g., Nrf2, NFkB, and HSF). Capitalizing on their identification and synthesis of these endogenous signaling mediators, Complexa's technologies act to amplify the existing anti-inflammatory and metabolic signaling mechanisms that promote the resolution and repair of acute and chronic tissue injury and disease.It is headquartered in Berwyn, Pennsylvania. | $62M | Series C | Jul 26, 2017 |  |
| Cydan | Cydan is an orphan drug accelerator that identifies and de-risks compounds with therapeutic and commercial potential. Their rigorous process generates data to support a development path and new company formation. Cydan’s experienced and globally networked team brings strong relationships with academia and patient advocacy, deep expertise in drugdevelopment, and a track record of successful product commercialization. | $16M |  | Apr 11, 2013 |  |
| Rhythm Pharmaceuticals | Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. Their lead peptide product candidate, setmelanotide, is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist for the treatment of raregenetic disorders of obesity. They believe that setmelanotide, for which they have exclusive worldwide rights, has the potential to serve as replacement therapy for the treatment of melanocortin 4, or MC4, pathway deficiencies. The MC4 pathway is a compelling target for treating these genetic disorders because of its critical role in regulating appetite and weight, and peptide therapeutics are uniquely suited to activating this target. | $33M | Series B | Nov 27, 2012 |  |
| Ablexis | Ablexis, LLC, a biotechnology company dedicated to developing an innovative, next-generation platform for antibody drug discovery, was founded in December 2009, based on technology principles established by its subsidiary, Aliva Biopharmaceuticals, Inc. | $12M | Series A | Jun 02, 2010 |  |
| Ixchelsis | Ixchelsis Ltd is a clinical-stage biotechnology company developing an oxytocin receptor antagonist (IX-01) for the treatment of premature ejaculation (PE). IX-01 is a clinical stage asset that has the potential to be the best in class pharmacological approach for the treatment of PE. To date IX-01 has completed a Phase 1 single ascending dose studyin healthy male volunteers and is currently being progressed through to clinical proof of concept (POC). Ixchelsis is funded by TVM Life Sciences Ventures VII and is lead by an excellent Management team with extensive experience in pharmaceutical R&D, particularly in the male sexual health therapeutic area. | $12M |  |  |  |
| Flexion Therapeutics | Flexion Therapeutics advances drug candidates through clinical proof of concept and beyond, in partnership with pharmaceutical and biotechnology companies. By providing expertise and sharing risk, Flexion effectively expands the portfolios of its partners. | $9M | Series A |  |  |

9 of 9 investments shown.

## Co-investors
- [Andera Partners](https://shizune.co/investors/profile/edmond-de-rothschild-investment-partners) — VC Fund, 4 deals together
- [SV Health Investors](https://shizune.co/investors/profile/sv-life-sciences) — VC Fund, 4 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 3 deals together
- [Novartis Venture Fund](https://shizune.co/investors/profile/novartis-venture-fund) — VC Fund, 3 deals together
- [Arix Bioscience](https://shizune.co/investors/profile/arix-bioscience) — VC Fund, 2 deals together
- [IP Group](https://shizune.co/investors/profile/ip-group-plc) — VC Fund, 2 deals together

## About Pfizer

VC Fund · New York, United States

Pfizer provides access to safe and effective and affordable medicines and health care services. They have a portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and they have an industry-leading pipeline of promising new products that havethe potential to challenge some of the most feared diseases of their time, like Alzheimer's disease and cancer.

5 contacts available at Pfizer.

| Name | Title | Profile |
| --- | --- | --- |
| Alessandra Leone | Global CMC Sr. Manager | https://shizune.co/investors/profile/alessandra-leone |
| Angela L Coral | Senior Manager, Partnerships & Impact Reporting, Global Health & Social Impact | https://shizune.co/investors/profile/angela-l-coral |
| Barbara Dalton | Senior Managing Partner, Pfizer Ventures; VP, Worldwide Business Development | https://shizune.co/investors/profile/barbara-dalton |
| Chris Boshoff | CSO | https://shizune.co/investors/profile/chris-boshoff |
| Chris O’Donnell | Partner, Pfizer Ventures & Executive Director, Emerging Sciences & Innovation | https://shizune.co/investors/profile/chris-o-donnell |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Barbara Dalton invest in?

Barbara Dalton invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Barbara Dalton last invest?

The most recent investment recorded for Barbara Dalton closed in Nov 2025. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co